AllSci News
US FDA approves Leqembi Iqlik for at-home subcutaneous initiation in early Alzheimer’s disease
The US FDA approved a supplemental Biologics License Application for Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer’s…
BMS seeking first FDA approval for molecular glue mezigdomide in heavily pretreated multiple myeloma
The US FDA has accepted for review a New Drug Application submitted by Bristol Myers Squibb (NYSE: BMY) for mezigdomide in combination with carfilzomib and...
Novartis signs up to access Chai Discovery’s AI antibody platform
San Francisco-based Chai Discovery announced a collaboration with Novartis under which the Swiss pharmaceutical company will gain access to Chai’s generative AI…
Voyager reports durable six-month preclin safety data for Alzheimer's gene therapy ahead of Phase I
Voyager Therapeutics (Nasdaq: VYGR) reported six-month preclinical toxicology data for VY1706 Alzheimer's gene therapy candidate at the Alzheimer's...
GSK's PD-1 dostarlimab moves closer to surgery-free treatment for locally advanced rectal cancer
GSK (NYSE: GSK) reported positive interim results on July 14 from the registrational AZUR-1 trial of dostarlimab (Jemperli) in patients with stage II/III...
Alkermes' alixorexton sustains narcolepsy wakefulness gains through nine months of extension study
Nine months of sustained wakefulness data from an ongoing long-term extension study of alixorexton narcolepsy treatment may be the most consequential...
Servier acquires Edgewise's muscular dystrophy business for USD 2.65 billion, gaining sevasemten rights
France-based Servier has completed its acquisition of the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up...
FDA clears path for Voxzogo's conversion from accelerated to traditional approval in achondroplasia
The US FDA has accepted BioMarin Pharmaceutical Inc.'s (Nasdaq: BMRN) supplemental New Drug Application (sNDA) for Voxzogo (vosoritide) seeking full...
AB Science narrows pipeline to AML and ALS programs, discontinues three suspended studies
France-based AB Science SA (Euronext: AB) is narrowing its clinical focus to two programs — AB8939 in relapsed/refractory acute myeloid leukemia and...
Apnimed files for Nasdaq IPO with NDA-stage sleep apnea therapy under FDA review
Cambridge, Massachusetts-based Apnimed, Inc. (Nasdaq: APMD) filed for an IPO on July 10, 2026, seeking a Nasdaq listing for a company whose sole clinical...
Zhaoke flips regional license into global ownership of late-stage myopia drop NVK002
Zhaoke Ophthalmology converts regional licensee status into global IP ownership of a late-stage myopia drop, leaving originator Nevakar with only a...
Eisai data support plasma tau tangle biomarker as pharmacodynamic readout for anti-tau therapy
Eisai's etalanetug reduced a tau tangle-specific plasma biomarker by more than 90% at nine months in patients with dominantly inherited Alzheimer's disease,...
Veraxa taps Ardigen AI to identify dual-target combinations for conditional cancer therapies
Veraxa Biotech AG (Nasdaq: VRXA) and Poland-based Ardigen S.A. announced an AI drug discovery collaboration to support target pair selection across Veraxa’s…
Ocugen expands OCU400 gene therapy footprint with MENA licensing deal ahead of Phase III readout
Ocugen (Nasdaq: OCGN) has signed a binding term sheet to license OCU400, its Phase III modifier gene therapy for retinitis pigmentosa, to Kuwait-based Roots...
Hemab reports early bleeding reduction with subcutaneous HMB-002 in Von Willebrand disease
Hemab Therapeutics (Nasdaq: COAG) presented Phase I/II data from its HMB-002 program in Von Willebrand Disease at the ISTH 2026 Congress, reporting...
The AllSci Brief
Systematic R&D and deal news. Daily.